Danaher appoints Christopher Riley to Executive Vice President for Biotechnology
Danaher Corporation announced that Christopher Riley has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its biotechnology business, effective January 1, 2024. Mr. Riley, currently Vice President and Group Executive of Danaher's Life Sciences company with responsibility for Genomic Medicines, will become an executive officer of Danaher reporting to President and Chief Executive Officer, Rainer Blair.
Rainer Blair commented: "Chris' leadership has helped drive the success of our genomic medicines and diagnostics businesses over the past six years. His strong track record of delivering results, passion for helping our customers and building winning teams, plus his deep commitment to the Danaher Business System, is a tremendous asset for Danaher. I look forward to seeing Chris apply his skills and experiences to ensuring the continued success of our Biotechnology business, as we support customers in their pursuit of life-changing breakthroughs for patients."
Mr. Riley joined Danaher in 2007. In his current role, in addition to his Genomic Medicines responsibilities, Chris oversees High Growth Markets and Pall Corporation at Danaher. Previously he was Vice President and Group Executive for Danaher's Diagnostics company and, prior to that, held various roles of increasing responsibility across multiple Danaher subsidiaries. Before joining Danaher, Chris worked for the Boston Consulting Group. He holds a Bachelor of Science degree in Mechanical Engineering from the University of Illinois, as well as a Master of Business Administration degree from Kellogg at Northwestern University.
Other news from the department people
